Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anixa Biosciences Inc (ANIX)

Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,190
  • Shares Outstanding, K 33,528
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,930 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.61

Options Overview Details

View History
  • Implied Volatility 135.74% (-152.63%)
  • Historical Volatility 45.20%
  • IV Percentile 9%
  • IV Rank 6.04%
  • IV High 1,012.25% on 03/30/26
  • IV Low 79.42% on 05/29/25
  • Expected Move (DTE 5) 0.48 (17.70%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 74
  • Volume Avg (30-Day) 339
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 2,933
  • Open Int (30-Day) 2,995
  • Expected Range 2.21 to 3.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 2
  • High Estimate $-0.08
  • Low Estimate $-0.10
  • Prior Year $-0.09
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.44 +10.25%
on 03/30/26
3.03 -11.22%
on 03/12/26
-0.29 (-9.73%)
since 03/10/26
3-Month
2.44 +10.25%
on 03/30/26
3.39 -20.65%
on 01/12/26
-0.69 (-20.41%)
since 01/09/26
52-Week
2.44 +10.25%
on 03/30/26
5.46 -50.70%
on 12/09/25
+0.03 (+1.13%)
since 04/10/25

Most Recent Stories

More News
RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation

ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...

KYNB : 7.17 (-0.28%)
ANIX : 2.69 (-1.82%)
GTBP : 0.3690 (-5.46%)
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026

Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trial

ANIX : 2.69 (-1.82%)
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026

Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trial

ANIX : 2.69 (-1.82%)
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

SAN JOSE, Calif. , April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.69 (-1.82%)
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants

ANIX : 2.69 (-1.82%)
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial status

ANIX : 2.69 (-1.82%)
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

SAN JOSE, Calif. , March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.69 (-1.82%)
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform

ANIX : 2.69 (-1.82%)
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data

ANIX : 2.69 (-1.82%)
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

ANIX : 2.69 (-1.82%)

Business Summary

Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.

See More

Key Turning Points

3rd Resistance Point 2.88
2nd Resistance Point 2.83
1st Resistance Point 2.76
Last Price 2.69
1st Support Level 2.64
2nd Support Level 2.58
3rd Support Level 2.51

See More

52-Week High 5.46
Fibonacci 61.8% 4.30
Fibonacci 50% 3.95
Fibonacci 38.2% 3.59
Last Price 2.69
52-Week Low 2.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.